PTEN and prostate carcinoma: Loss of PTEN tumor suppressor is frequently reported in aberrant activation of this pathway implicated not only in survival and growth of prostate cancer cells but also in tumor metastasis (Cohen-Solal et al., 2015; Ciccarese et al., 2017; Statz et al., 2017).